オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - teriparatide, quantity: 250 microgram - injection, solution - excipient ingredients: glacial acetic acid; sodium acetate; hydrochloric acid; mannitol; sodium hydroxide; water for injections; metacresol - forteo is indicated for the treatment of osteoporosis in postmenopausal women and the treatment of primary osteoporosis in men when other agents are considered unsuitable and when there is a high risk of fractures. forteo is indicated for the treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at high risk for fracture.

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - teriparatide 0.25 mg/ml (as acetate) - solution for injection - 250 mcg/ml - active: teriparatide 0.25 mg/ml (as acetate) excipient: glacial acetic acid hydrochloric acid mannitol metacresol nitrogen sodium acetate sodium hydroxide water for injection - teriparatide bnm is indicated for the treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at high risk for fracture.

イスラエル - 英語 - Ministry of Health

eli lilly israel ltd, israel - teriparatide - solution for injection - teriparatide 250 mcg/ml - teriparatide - teriparatide - treatment of postmenopausal women with osteoporosis at high risk for fracture:forteo is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. in postmenopausal women with osteoporosis, forteo increases bmd reduces the risk of vertebral and nonvertebral fractures . increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture :forteo is indicated to increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy . treatment of men and women with glucocorticoid-induced osteoporosis at high risk for fracture:forteo is indicated for the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy .

マルタ - 英語 - Medicines Authority

teva b.v. swensweg 5, 2031 ga haarlem, netherlands - teriparatide - solution for injection in a pre-filled pen - teriparatide 20/80 µg/µl - calcium homeostasis

イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - teriparatide - solution for injection - 250microgram/1ml

イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - teriparatide - solution for injection - 250microgram/1ml

日本 - 英語 - すりの適正使用協議会 RAD-AR Council, Japan

asahi kasei pharma corporation - teriparatide acetate - injection

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

teva b.v. - teriparatide - solution for injection in pre-filled pen - 20/80 - parathyroid hormones and analogues; teriparatide

欧州連合 - 英語 - EMA (European Medicines Agency)

stada arzneimittel ag - teriparatide - osteoporosis - calcium homeostasis - movymia is indicated in adults.treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. in postmenopausal women, a significant reduction in the incidence of vertebral and non vertebral fractures but not hip fractures has been demonstrated.treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.

欧州連合 - 英語 - EMA (European Medicines Agency)

gedeon richter plc. - teriparatide - osteoporosis - calcium homeostasis - terrosa is indicated in adults.treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. in postmenopausal women, a significant reduction in the incidence of vertebral and non vertebral fractures but not hip fractures has been demonstrated.treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.